首页> 美国卫生研究院文献>Elsevier Public Health Emergency Collection >Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
【2h】

Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects

机译:肺纤维化治疗中药的研究进展及未来展望

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progression to respiratory failure. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. Recent data have shown the anti-fibrotic benefits of the active ingredients from TCM in this field, which may represent an attractive source of the drug discovery against PF.
机译:肺纤维化(PF)是一种慢性的,使人衰弱并且经常致命的肺部疾病。尽管在众多研究人员的努力下,PF的分子机制已逐渐明朗,但几乎没有开发出有效的药物来逆转人类PF甚至阻止慢性发展为呼吸衰竭。中医(TCM)是5000多年的医疗实践的主要组成部分(尤其是在中国),在治疗人类疾病方面通常比以前尝试的方法具有更广泛的作用范围。最近的数据表明,该领域中草药有效成分具有抗纤维化作用,这可能是抗PF药物发现的诱人来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号